Jeff McIntyre, MA, of the Global Liver Institute, discussed how the delayed diagnosis of nonalcoholic steatohepatitis (NASH) affects patients and how health care and managed care professionals can help expedite diagnosis and treatment.
Jeff McIntyre, MA, of the Global Liver Institute (GLI), discussed how delayed diagnosis, or underdiagnosis, of non-alcoholic steatohepatitis (NASH) affects patients and explained how both health care and managed care professionals can help prevent it.
At the Global Liver Institute, McIntyre is the vice president of liver health programs. Within this position, he supervises GLI's liver health program portfolio, including NASH and liver cancer. To address disparities in screening and treatment globally, McIntyre works with program directors to identify patient engagement opportunities across all pathways, including drug development, regulatory input, and educational opportunities.
Transcript
How does the delayed or underdiagnosis of NASH affect patient outcomes? What strategies can health care professionals and managed care organizations use to expedite diagnosis and treatment?
It's really significant because most of the symptoms for fatty liver disease, and even early-stage NASH, are what they refer to as silent, or, at the very least, they're obscured by other disease conditions, as well.
Patients may have a feeling of fatigue or a little bit of nausea of some sort. Until they actually get a liver stiffness test or some sort of non-invasive blood tests done, it's difficult to tell whether they actually have liver disease or not. Quite often, NASH is not diagnosed until it's very, very advanced. At that point, patients are looking at some difficult choices to make with their management.
I think for managed care organizations, and folks in the managed care space, what's most important is that the resolution for NASH is ultimately going to be a multi-pharmacy approach. While you are treating diabetes, or high cholesterol, or any other variety of conditions that a patient may have, make sure that the liver tests are run or that any of the other medications they may need for fatty liver disease are also in play.
Following Roe v Wade Overturn, Research Focuses on Male Contraceptives
May 6th 2024Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen